New shigella vaccine shows promise for infants in phase 2 trial
NCT ID NCT06523231
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 1 time
Summary
This study tested a new vaccine called Shigella4V2 to protect infants against shigellosis, a severe diarrheal disease. Researchers gave the vaccine to 110 healthy 9-month-old babies to check its safety and how well it triggers an immune response. The goal is to find the best dose to prevent this common infection in young children.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SHIGELLOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
KEMRI - Center for Global Health Research
Kisumu, 578,40100, Kenya
More trials for these conditions
Other studies related to the condition(s) this trial covers.